Development of a Novel Rolling-Tube Cell Culture Platform and Demonstration of System Feasibility - A new rolling-tube system balances scale-up accuracy and thoroughput. - BioPharm International

ADVERTISEMENT

Development of a Novel Rolling-Tube Cell Culture Platform and Demonstration of System Feasibility
A new rolling-tube system balances scale-up accuracy and thoroughput.


BioPharm International
Volume 23, Issue 8

ABSTRACT

This article describes and demonstrates the performance of a novel disposable culture platform, the rolling tube, which we have developed, tested, and found superior, in many aspects, compared with current platforms being used in process development applications such as media screening and clone selection. The rolling-tube platform provides a balance between throughput and scale or volume (necessary to perform analytical assays); it also is robust, easy to set up, and ergonomic to use, as well as versatile, saving time and money. Importantly, results obtained with this system are applicable to larger platforms used in commercial production. This platform is now being implemented in our laboratories in California and Europe.


EDEN BIODESIGN
Throughput, robustness, and low cost are major system requirements in cell culture process development projects, ranging from clone selection to media screening. A desirable system also should allow for sufficient sample volumes to perform a comprehensive analysis for testing metabolites, viable cell growth, product titer, and quality attributes. Ideally, the system would closely mimic the outcome in production bioreactors and thus provide high confidence in obtaining a beneficial outcome following scale-up and implementation.

Disposability is now common across a growing spectrum of platform scales.1 Traditionally, 2-L roller bottles on a rolling device placed in a humidified, temperature and CO2-controlled incubator served as a common screening system for the aforementioned applications, toward implementation in perfusion, batch, and fed-batch bioreactors. They are inexpensive and disposable, provide a low-shear culture environment, and often demonstrate predictability of culture behavior following scale-up, making them a good choice compared to other small-scale platforms such as spinner and shake flasks. However, their size, rolling equipment space requirements, and cumbersome handling are major drawbacks that limit throughput. They also are wasteful because smaller volumes of culture and spent-media usually are required for titer, potency, and spent-media and metabolite analysis.

The volume of the 2-L roller bottles is not large enough to allow purification and a comprehensive characterization of the product or impurities. Smaller, low-cost platforms such as T-flasks and plate systems have advantages in throughput, space use, and ease of use while allowing for sufficient sample volume for analysis and being predictive of performance at large scale. In previous experiments, we have found that T-flasks performed similarly or even better than the large roller bottles (not shown). However, both flask and plate systems have drawbacks such as ergonomics and gas transfer and condensation problems resulting from their design combined with lower volume (especially multi-well plates) that can significantly affect culture performance. Therefore, we set out to develop a platform that would preserve the advantages of the traditional roller bottle along with those of the more advanced flask and plate systems. Here, we describe the performance of the roller tube platform compared to two small-scale platforms: T-flasks and 6-well plates.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here